Previsión
El precio objetivo medio de los analistas es de 33,38 € (+6,31 %). La mediana es de 35,54 € (+13,18 %).
| Comprar |
17 |
| Mantener |
7 |
| Vender |
1 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Acadia Healthcare sees $200m EBITDA potential from 3,000 new beds
At the Jefferies conference Acadia Healthcare said demand for behavioral health services remains strong while the company works to convert the 3,000 beds opened since 2023 into stable earnings and cash flow. Management cited receivable write-offs, claim denials and start-up losses as near-term headwinds but is confident it can realize about $200 million of incremental EBITDA through accreditations, contract negotiations with payers and higher occupancy. CEO Debbie Osteen promised a “return to basics” and tight execution; one new facility already reached break-even in about a year. The company reports stabilized daily revenues, improved employee retention and expects pressure from receivable write-offs to ease over the course of the year. » Más en de.investing.com
Acadia Healthcare: KeyBanc raises price target to 40 USD after rising occupancy rates
KeyBanc has raised its price target for Acadia Healthcare to 40 USD, driving the stock on high volume. The reason is growing occupancy rates in the psychiatric clinics and ongoing capacity expansions. Analysts see further substantial upside for the U.S. clinic operator against the backdrop of the mental-health megatrend. » Más en finanzen.net
Acadia Healthcare hits new 52-week high at $32.82
Acadia Healthcare’s stock rose to a 52-week high of $32.82, gaining 43.92% over the past year. Over the past six months the price increased by 165%, and year-to-date by 123%. Analyst updates, including upgrades from Jefferies and affirmed overweight ratings from KeyBanc, highlight operational improvements under new management and further growth potential. An InvestingPro analysis currently rates the stock as undervalued and sees additional upside potential. » Más en de.investing.com
Acadia Healthcare sees analyst upgrades but faces bad-debt headwinds
Analysts raised ratings and price targets after Acadia Healthcare reported a strong Q1 and modestly increased 2026 earnings and EBITDA guidance, with Raymond James upgrading to Strong Buy and lifting its target to $39. Cantor Fitzgerald raised its target to $30 but kept a Neutral rating, citing escalating bad debt and claim denials that offset some operational improvements. Acadia is pursuing $200 million in recoveries from underperforming locations while maintaining modest growth, leaving short-term outlooks uncertain despite positive core performance. » Más en finance.yahoo.com
Acadia Healthcare gets lifted price targets from RBC and Raymond James after Q1 beat
RBC Capital raised its price target on Acadia Healthcare to $31 from $28 and reiterated an Outperform rating after the company beat fiscal Q1 expectations. Raymond James upgraded the stock to Strong Buy, boosting its target to $39 from $25 and modestly raising its 2026 EBITDA and earnings outlook. Raymond James said Acadia can harvest about $200M from underperforming facilities and expects modest underlying growth driving higher estimates and a richer multiple. » Más en finance.yahoo.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasEn 2022, Acadia Healthcare ya ha pagado 0,72 € en dividendos. El último pago fue en febrero de 2022.
Datos financieros
En el último trimestre, Acadia Healthcare tuvo unos ingresos de 790,42 M € y un beneficio neto de 30,45 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 790,42 M | 8,93 % |
| Beneficio bruto | 152,5 M | 78,21 % |
| Beneficio neto | 30,45 M | 1,43 % |
| EBITDA | 129,67 M | 22,65 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 2931,49 M € |
Número de acciones | 92,97 M |
Máximo/mínimo de 52 semanas | 36,18 € - 10,42 € |
| Dividendos | No |
Beta | 0,63 |
Ratio P/E | -2,77 |
Ratio PEG | 0,00 |
Ratio P/B | 1,55 |
Ratio P/S | 0,94 |
Perfil de la empresa
Acadia Healthcare Company, Inc. desarrolla y opera centros psiquiátricos de hospitalización, centros de tratamiento residencial, hogares grupales, centros de tratamiento de abuso de sustancias y centros ambulatorios de salud conductual para atender las necesidades de salud conductual y recuperación de las comunidades en Estados Unidos y Puerto Rico. La compañía opera centros psiquiátricos agudos de hospitalización, que se encargan de estabilizar a pacientes que representan una amenaza para sí mismos o que requieren observación las 24 horas, intervención diaria y monitoreo por psiquiatras; y centros de tratamiento especializado, incluidos centros de recuperación residencial y de trastornos de la conducta alimentaria, y centros de tratamiento integral que ofrecen atención continua para adultos con trastornos adictivos y trastornos mentales concurrentes. También ofrece centros de tratamiento residencial, que tratan a pacientes con trastornos de conducta en un entorno no hospitalario, incluidos programas al aire libre; y ofrecen colocación terapéutica para niños y adolescentes con trastornos emocionales. Al 28 de febrero de 2022, operaba una red de 228 centros de atención de salud conductual con aproximadamente 10.500 camas. Acadia Healthcare Company, Inc. fue fundada en 2005 y tiene su sede en Franklin, Tennessee.
| Nombre | Acadia Healthcare |
| CEO | Debra K. Osteen |
| Sede | Franklin,
tn Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Proveedores y servicios sanitarios |
| Salida a bolsa | 07/12/2015 |
| Empleados | 22.000 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | ACHC |
Frankfurt | 7RA.F |
Düsseldorf | 7RA.DU |
München | 7RA.MU |